Rare diseases and orphan medicines: knowledge and perceptions of healthcare professionals and the public

被引:0
|
作者
Vassallo, Sharon [1 ]
Pizzuto, Maresca Attard [1 ]
Azzopardi, Lilian M. [1 ]
Serracino-Inglott, Anthony [1 ]
机构
[1] Univ Malta, Dept Pharm, Msida, Malta
关键词
healthcare professionals; orphan medicines; perception; public; rare diseases;
D O I
10.1093/jphsr/rmac036
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives The aim of this study was to assess the public's and healthcare professionals' awareness and perception on rare diseases and orphan drugs, and to identify challenges faced by both populations. Methods Two questionnaires, one for healthcare professionals and one for the public including rare disease patients, were developed, validated and disseminated. The experience and awareness of the public and healthcare professionals with regard to rare diseases and orphan medicines were analysed. Key findings The questionnaires were completed by 228 members of the public and 73 healthcare professionals. Thirty-seven percent of the public knew or were related to someone with a rare disease. Public participants consisted of those who knew or were related to someone with a rare disease (37%) and rare disease patients (12%). Nineteen percent of rare disease patients had encountered problems while trying to obtain an orphan drug. Seventy-three healthcare professionals completed the questionnaire. Fifty-five percent had diagnosed, encountered or examined a rare disease patient at a point in their career, while 32% had dispensed or tried to dispense an orphan drug. Twenty-seven percent of healthcare professionals had encountered various problems while trying to obtain an orphan drug for patients. Conclusions The elucidation of public's perception on rare diseases can offer better guidelines for healthcare professionals to support rare disease patients better.
引用
收藏
页码:393 / 395
页数:3
相关论文
共 50 条
  • [41] The concept of rare or orphan diseases in epilepsy
    Baulac, M.
    [J]. EPILEPSIA, 2006, 47 : 238 - 238
  • [42] Living in the light of rare and orphan diseases
    Gershkowitz, Levi G.
    [J]. MOLECULAR GENETICS AND METABOLISM, 2014, 111 (02) : S45 - S46
  • [43] ORPHAN AND RARE DISEASES - THE PAYER PERSPECTIVE
    Spoors, J.
    Rietveld, A.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A542 - A542
  • [44] Orphan drugs and rare diseases in Andorra
    Gea, E.
    Gil, E.
    Barral, N.
    Gonzalez, V.
    Soler, A.
    Avellanet, M.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2013, 35 (05) : 963 - 963
  • [45] Novel orphan medicines and abandoned pathways - the US Orphan Drug Act of 1983 and the impact on rare rheumatologic diseases and lysosomal storage disorders
    Markus Ries
    Thomas Lutz
    Anette Lampert
    William Mountford
    Konstantin Mechler
    Georg F Hoffmann
    [J]. Molecular and Cellular Pediatrics, 2 (Suppl 1)
  • [46] Preface - Rare or orphan lung diseases
    Prakash, UBS
    [J]. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2002, 23 (02) : 83 - 84
  • [47] Presentation of the rare and orphan diseases symposium
    Blin, Olivier
    Schwebig, Annick
    [J]. PRESSE MEDICALE, 2010, 39 (05): : 3 - 4
  • [48] The portal for rare diseases and orphan drugs
    Singh, Jatinder
    [J]. JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2013, 4 (02) : 168 - 169
  • [49] Knowledge of Adverse Drug Reaction Reporting and the Pharmacovigilance of Biological Medicines: A Survey of Healthcare Professionals in Ireland
    O'Callaghan, J.
    Griffin, B. T.
    Morris, J. M.
    Bermingham, Margaret
    [J]. BIODRUGS, 2018, 32 (03) : 267 - 280
  • [50] Knowledge of Adverse Drug Reaction Reporting and the Pharmacovigilance of Biological Medicines: A Survey of Healthcare Professionals in Ireland
    J. O’Callaghan
    B. T. Griffin
    J. M. Morris
    Margaret Bermingham
    [J]. BioDrugs, 2018, 32 : 267 - 280